However, this oncogenic monopoly is not universal; CTNNB1 mutations often replace APC loss in hepatocellular carcinoma (HCC) and medulloblastoma, highlighting the context-dependent nature of WNT perturbation (Zhao et al., 2022; Nie et al., 2020). The gene discussed is APC; the disease is hepatocellular carcinoma.